格隆汇9月25日丨郑中设计(002811.SZ)公布，控股股东深圳市亚泰一兆投资有限公司（简称"亚泰一 兆"）自本公告披露之日起15个交易日后的3个月内，以集中竞价和大宗交易方式减持公司股份不超过 8,997,606股（占公司剔除回购专用账户中股份数量后总股本比例不超过3%）。其中，以集中竞价交易 方式减持股份数量不超过2,999,202股（占公司剔除回购专用账户中股份数量后总股本比例不超过 1%），以大宗交易方式减持股份数量不超过5,998,404股（占公司剔除回购专用账户中股份数量后总股 本比例不超过2%）。 ...

| | | 9月23日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 初灵信息 | 中移基金持有摩尔线程约2.12%,公司合计间接持股0.0229% | | 项目投资 | 沃尔核材 | 控股子公司拟不超过10亿元投建科特(苏州)新材料项目 | | 合同中标 | 平高电气 | 中标13.69亿元国家电网输变电项目 | | 股权收购 | 爱梦室 | 拟以1900万元收购湖北永怡30%的股权 | | 回购 | 神马股份 | 拟斥资1亿元至2亿元回购股份 | | 即版 | 东山精密 | 筹划发行H股股票并在香港联合交易所上市相关事项 | | | 格林美 | 向香港联交所递交H股发行上市申请并刊发申请资料 | | 增减持 | 南兴股份 | 控股股东拟减持不超过3%股份 | | | 华凯易佰 | 董事长、总经理之配偶拟增持不低于2000万元公司股份 | | | 中科江南 | 众志软科拟减持不超过1.73%股份 | | 其他 | 万安科技 | 收到集中采购定点通知书 | | | 青龙管业 | 与中材国际签署战略合作协议 日制室に | 【热点】 初灵信息(3002 ...

于本公布日期，现有股份于联交所买卖每手买卖单位为8000股现有股份。现建议将股份于联交所买卖每 手买卖单位由8000股现有股份更改为4000股合并股份，惟须待股份合并生效后方可作实。 于本公布日期，公司有7,687,158,040股已缴足或入账列作缴足的已发行现有股份(包括库存股份)。假设 自本公布日期起直至股份合并生效日期期间不再发行或购回股份，于股份合并生效后，公司将有 1,537,431,608股缴足或入账列作缴足的已发行合并股份。 格隆汇9月25日丨中国文旅农业(00542.HK)公告，董事会建议实行股份合并，基准为每五(5)股每股面值 港币0.01元已发行及未发行现有股份将合并为一(1)股每股面值港币0.05元的合并股份。股份合并须待(其 中包括)股东于股东特别大会上批准后方可作实。 ...

Core Insights - The company, Nine Dragons Paper (02689.HK), reported a 9.6% increase in sales volume to approximately 21.5 million tons for the fiscal year ending June 30, 2025 [1] - Revenue rose by approximately 6.3% to 63.241 billion yuan, driven by the increase in sales volume despite a 3.0% decrease in average selling price [1] - Gross profit increased by approximately 26.9% to 7.245 billion yuan, with the gross profit margin improving from 9.6% in the 2024 fiscal year to about 11.5% in the 2025 fiscal year [1] - The profit attributable to equity holders surged by approximately 135.4% to 1.767 billion yuan, translating to basic earnings per share of 0.38 yuan [1] Revenue and Sales Performance - Sales volume increased by 9.6% to around 21.5 million tons [1] - Revenue grew by approximately 6.3% to 63.241 billion yuan, influenced by the sales volume increase [1] - Average selling price experienced a decrease of about 3.0%, impacting overall revenue [1] Profitability Metrics - Gross profit rose by approximately 26.9% to 7.245 billion yuan [1] - Gross profit margin improved from 9.6% to approximately 11.5% due to a larger decline in raw material costs compared to product prices [1] - Profit attributable to equity holders increased by approximately 135.4% to 1.767 billion yuan [1]

格隆汇9月25日丨蒙牛乳业(02319.HK)发布公告，2025年9月25日耗资429.6万港元回购30万股，回购价 格每股14.24-14.35港元。 ...

格隆汇9月25日丨国投丰乐(000713.SZ)公布，近日收到控股股东国投种业科技有限公司（简称"国投种 业"）出具的《关于自愿延长股份锁定期的承诺函》，基于对公司未来发展的信心及价值判断，为促进 公司持续、稳定、健康发展，维护广大投资者利益，自愿承诺延长其持有的122,802,996股公司股份的锁 定期。国投种业承诺通过协议转让已取得的122,802,996股国投丰乐股份，锁定期到期日由2025年10月25 日延长至2028年10月25日。 ...

Group 1 - Company Hualian Holdings (000036.SZ) plans to invest RMB 50 million in Chengdu Ideal Realm Technology Co., Ltd. (referred to as "Ideal Realm") through a capital increase agreement, acquiring a 2.7778% stake in the company [1][2] - The investment will consist of RMB 4.4924 million for subscribing to the new registered capital, with the remaining RMB 49.955076 million allocated to capital reserves [1] - The related party, Shenzhen Hengyu Capital Management Co., Ltd. (referred to as "Hengyu Capital"), will also invest RMB 100 million in Ideal Realm, obtaining a 5.555556% stake after the capital increase [2] Group 2 - Hengyu Capital has the option to designate an associated third party to invest RMB 50 million under the same conditions as its own investment [2] - Ideal Realm's main business focuses on AR glasses and vehicle display technology, with its self-developed Fiber Scanning Display (FSD) technology being distinct from semiconductor processes [2] - The AR glasses produced by Ideal Realm are characterized by a small target area, low power consumption, and high PPI, catering to the consumer market [2]

Core Viewpoint - Mees Health (02415.HK) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for gout patients [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment for patients during both acute and intercritical phases of gout through a combination of prospective and retrospective observational studies [1] - The project is valued at approximately RMB 21 million [1] - The group leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies, thereby providing digital solutions to enhance the healthcare ecosystem and improve medical quality [1]

Group 1 - The core point of the article is the appointment of Liu Hui as the Executive Director and General Manager of China Shipbuilding Leasing, effective from September 25, 2025 [1] - Liu Hui will also serve as a member of the Strategic and Investment Committee, as well as the ESG and Sustainable Development Committee [1]

格隆汇9月25日丨酷派集团(02369.HK)公告，9月25日耗资137.5万港元回购108.8万股。 ...